CARDURA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cardura, and when can generic versions of Cardura launch?
Cardura is a drug marketed by Viatris and is included in two NDAs.
The generic ingredient in CARDURA is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cardura
A generic version of CARDURA was approved as doxazosin mesylate by APOTEX on October 18th, 2000.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CARDURA?
- What are the global sales for CARDURA?
- What is Average Wholesale Price for CARDURA?
Summary for CARDURA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 106 |
| Clinical Trials: | 11 |
| Patent Applications: | 1,730 |
| Drug Prices: | Drug price information for CARDURA |
| What excipients (inactive ingredients) are in CARDURA? | CARDURA excipients list |
| DailyMed Link: | CARDURA at DailyMed |
Recent Clinical Trials for CARDURA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The University of Texas Health Science Center, Houston | Phase 1 |
| Brown University | Phase 2 |
| University of California, Los Angeles | Phase 3 |
Pharmacology for CARDURA
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
US Patents and Regulatory Information for CARDURA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-001 | Nov 2, 1990 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-004 | Nov 2, 1990 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-002 | Nov 2, 1990 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-003 | Nov 2, 1990 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CARDURA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-001 | Nov 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-004 | Nov 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-003 | Nov 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-002 | Nov 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CARDURA
See the table below for patents covering CARDURA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Belgium | 871771 | ⤷ Sign Up | |
| South Africa | 7806184 | ⤷ Sign Up | |
| India | 148828 | A PROCESS FOR PREPARING 4 AMINO-2-(PIPERIZIN-1-YL ORHOMOPIPERAZIN-1YL)QUINA ZOLINE | ⤷ Sign Up |
| Bosnia and Herzegovina | 98216 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
